Hermetica Superfood Encyclopedia
The Short Answer
A specialized probiotic naturally found in breastfed infants that supports early immune development, reduces gut inflammation, and helps manage IBS symptoms in adults.
CategoryProbiotic & Fiber
GroupFermented/Probiotic
Evidence LevelModerate
Synergy Pairings4
Health Benefits
Establishes a healthy gut microbiome in infants by efficiently metabolizing human milk oligosaccharides (HMOs).
Enhances immune system development and reduces the risk of infections in early life.
Reduces systemic inflammation and supports regulatory immune balance through short-chain fatty acid (SCFA) production.
Improves symptoms of irritable bowel syndrome (IBS), diarrhea, and gut permeability in adults.
Promotes nutrient absorption and supports the uptake of essential vitamins and minerals.
Protects against pathogenic bacteria and strengthens the gut barrier function
Origin & History
Bifidobacterium longum subspecies infantis (B. infantis) is a gram-positive, lactic acid-producing probiotic bacterium native to the gut of breastfed infants. It uniquely metabolizes human milk oligosaccharides (HMOs), playing a critical role in early gut colonization, immune system development, and microbiome balance. This extensively studied strain offers significant anti-inflammatory and digestive health benefits, extending its efficacy to adults for immune modulation and gut integrity.
“Bifidobacterium longum subsp. infantis has been a natural component of the microbiota in breastfed infants for millennia, playing an unacknowledged but critical role in foundational immune health. Its specific identification and therapeutic application are modern developments, extending its use across the lifespan for its profound anti-inflammatory and gut-stabilizing effects.”Traditional Medicine
Scientific Research
Extensive clinical studies support the efficacy of B. infantis in establishing a healthy infant microbiome, programming immune responses, and reducing inflammatory gastrointestinal conditions. Research consistently documents its short-chain fatty acid (SCFA)-mediated mechanisms in both infant and adult health.
Preparation & Dosage
Supplements
Available in capsule, powder, or liquid forms, often included in infant formulas and specialized probiotic blends.
Dosage
Typically 1–10 billion CFUs (colony-forming units) daily, adjusted based on age, product formulation, and specific health needs.
Pairing
Often co-administered with prebiotics such as human milk oligosaccharides (HMOs) or galactooligosaccharides (GOS) for enhanced colonization and synergistic effects.
Application
Suitable for infants, children, and adults to support foundational gut and immune resilience.
Nutritional Profile
- Live Probiotic Cultures: Bifidobacterium longum subsp. infantis (1-10 billion CFUs per serving)
- Short-Chain Fatty Acids (SCFAs): Acetate and butyrate, supporting gut epithelial health and anti-inflammatory responses.
- Human Milk Oligosaccharide (HMO) Metabolizers: Enzymes that break down complex oligosaccharides.
- Immunomodulatory Compounds: Activate T-regulatory cells and reduce pro-inflammatory cytokines (e.g., IL-6, TNF-α).
Synergy Stack
Hermetica Formulation Heuristic
Prebiotic matrix
Gut & Microbiome | Immune & Inflammation
Frequently Asked Questions
What is Bifidobacterium longum subspecies infantis?
B. infantis is a probiotic bacterium uniquely adapted to thrive in the infant gut by metabolizing human milk oligosaccharides (HMOs). It plays a foundational role in early immune development and gut barrier formation, and has also been clinically studied for IBS relief in adults.
Is B. infantis safe and what is the recommended dosage?
B. infantis is considered very safe for infants, children, and adults. Clinical trials in infants typically use 1-10 billion CFU daily, while the well-studied adult strain B. infantis 35624 has been used at 1 billion CFU/day for IBS. It should be taken with food and separated from antibiotics by at least 2 hours.
How does B. infantis differ from regular Bifidobacterium longum?
While both belong to the B. longum species, B. infantis is uniquely equipped with enzymes to fully metabolize human milk oligosaccharides, making it the dominant colonizer in breastfed infant guts. The adult strain B. infantis 35624 (Alflorex) has specific clinical evidence for reducing IBS symptoms including bloating, pain, and bowel irregularity.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
